Kathy K Byrd1, John G Hou2, Tim Bush1, Ron Hazen2, Heather Kirkham2, Ambrose Delpino3, Paul J Weidle1, Michael D Shankle4, Nasima M Camp5, Sumihiro Suzuki6, Patrick G Clay7. 1. Division of Human Immunodeficiency Virus (HIV)/ Acquired Immunodeficiency Syndrome (AIDS) Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia. 2. Health Analytics, Research, and Reporting, Walgreen Company, Deerfield, Illinois. 3. Patient Care and Advocacy Department, Walgreen Company, Deerfield, Illinois. 4. HealthHIV, Washington, District of Columbia. 5. Department of Health, Research, Informatics, and Technology, ICF, Atlanta, Georgia. 6. Department of Biostatistics and Epidemiology, University of North Texas Health Science Center, Fort Worth. 7. Department of Pharmacotherapy, System College of Pharmacy, University of North Texas Health Science Center, Fort Worth.
Abstract
BACKGROUND: Human immunodeficiency virus (HIV) viral suppression (VS) decreases morbidity, mortality, and transmission risk. METHODS: The Patient-centered HIV Care Model integrated community-based pharmacists with HIV medical providers and required them to share patient clinical information, identify therapy-related problems, and develop therapy-related action plans.Proportions adherent to antiretroviral therapy (proportion of days covered [PDC] ≥90%) and virally suppressed (HIV RNA <200 copies/mL), before and after model implementation, were compared. Factors associated with postimplementation VS were determined using multivariable logistic regression; participant demographics, baseline viral load, and PDC were explanatory variables. PDC was modified to account for time to last viral load in the year postimplementation, and stratified as <50%, 50% to <80%, 80% to <90%, and ≥90%. RESULTS: The 765 enrolled participants were 43% non-Hispanic black, 73% male, with a median age of 48 years; 421 and 649 were included in the adherence and VS analyses, respectively. Overall, proportions adherent to therapy remained unchanged. However, VS improved a relative 15% (75% to 86%, P < .001). Higher PDC (adjusted odds ratio [AOR], 1.74 per 1-level increase in PDC category [95% confidence interval {CI}, 1.30-2.34]) and baseline VS (AOR, 7.69 [95% CI, 3.96-15.7]) were associated with postimplementation VS. Although non-Hispanic black persons (AOR, 0.29 [95% CI, .12-.62]) had lower odds of suppression, VS improved a relative 23% (63% to 78%, P < .001). CONCLUSIONS: Integrated care models between community-based pharmacists and primary medical providers may identify and address HIV therapy-related problems and improve VS among persons with HIV. Published by Oxford University Press for the Infectious Diseases Society of America 2019.
BACKGROUND:Human immunodeficiency virus (HIV) viral suppression (VS) decreases morbidity, mortality, and transmission risk. METHODS: The Patient-centered HIV Care Model integrated community-based pharmacists with HIV medical providers and required them to share patient clinical information, identify therapy-related problems, and develop therapy-related action plans.Proportions adherent to antiretroviral therapy (proportion of days covered [PDC] ≥90%) and virally suppressed (HIV RNA <200 copies/mL), before and after model implementation, were compared. Factors associated with postimplementation VS were determined using multivariable logistic regression; participant demographics, baseline viral load, and PDC were explanatory variables. PDC was modified to account for time to last viral load in the year postimplementation, and stratified as <50%, 50% to <80%, 80% to <90%, and ≥90%. RESULTS: The 765 enrolled participants were 43% non-Hispanic black, 73% male, with a median age of 48 years; 421 and 649 were included in the adherence and VS analyses, respectively. Overall, proportions adherent to therapy remained unchanged. However, VS improved a relative 15% (75% to 86%, P < .001). Higher PDC (adjusted odds ratio [AOR], 1.74 per 1-level increase in PDC category [95% confidence interval {CI}, 1.30-2.34]) and baseline VS (AOR, 7.69 [95% CI, 3.96-15.7]) were associated with postimplementation VS. Although non-Hispanic black persons (AOR, 0.29 [95% CI, .12-.62]) had lower odds of suppression, VS improved a relative 23% (63% to 78%, P < .001). CONCLUSIONS: Integrated care models between community-based pharmacists and primary medical providers may identify and address HIV therapy-related problems and improve VS among persons with HIV. Published by Oxford University Press for the Infectious Diseases Society of America 2019.
Entities:
Keywords:
HIV; antiretroviral therapy; medication adherence; patient-centered HIV care model; sustained virologic response
Authors: Gary Marks; Unnati Patel; Michael J Stirratt; Michael J Mugavero; William C Mathews; Thomas P Giordano; Nicole Crepaz; Lytt I Gardner; Cynthia Grossman; Jessica Davila; Meg Sullivan; Charles E Rose; Christine OʼDaniels; Allan Rodriguez; Andrew J Wawrzyniak; Matthew R Golden; Shireesha Dhanireddy; Jacqueline Ellison; Mari-Lynn Drainoni; Lisa R Metsch; Edward R Cachay Journal: J Acquir Immune Defic Syndr Date: 2016-10-01 Impact factor: 3.731
Authors: Huldrych F Günthard; Michael S Saag; Constance A Benson; Carlos del Rio; Joseph J Eron; Joel E Gallant; Jennifer F Hoy; Michael J Mugavero; Paul E Sax; Melanie A Thompson; Rajesh T Gandhi; Raphael J Landovitz; Davey M Smith; Donna M Jacobsen; Paul A Volberding Journal: JAMA Date: 2016-07-12 Impact factor: 56.272
Authors: Kathy K Byrd; Felicia Hardnett; Patrick G Clay; Ambrose Delpino; Ron Hazen; Michael D Shankle; Nasima M Camp; Sumihiro Suzuki; Paul J Weidle Journal: AIDS Patient Care STDS Date: 2019-01-16 Impact factor: 5.078
Authors: Paul G Farnham; Chaitra Gopalappa; Stephanie L Sansom; Angela B Hutchinson; John T Brooks; Paul J Weidle; Vincent C Marconi; David Rimland Journal: J Acquir Immune Defic Syndr Date: 2013-10-01 Impact factor: 3.731
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Leslie Cottle; Xinyi C Zhang; Joseph Makhema; Lisa A Mills; Ravindre Panchia; Sharlaa Faesen; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David D Celentano; Max Essex; Sarah E Hudelson; Andrew D Redd; Thomas R Fleming Journal: N Engl J Med Date: 2016-07-18 Impact factor: 91.245
Authors: Alison J Rodger; Valentina Cambiano; Tina Bruun; Pietro Vernazza; Simon Collins; Jan van Lunzen; Giulio Maria Corbelli; Vicente Estrada; Anna Maria Geretti; Apostolos Beloukas; David Asboe; Pompeyo Viciana; Félix Gutiérrez; Bonaventura Clotet; Christian Pradier; Jan Gerstoft; Rainer Weber; Katarina Westling; Gilles Wandeler; Jan M Prins; Armin Rieger; Marcel Stoeckle; Tim Kümmerle; Teresa Bini; Adriana Ammassari; Richard Gilson; Ivanka Krznaric; Matti Ristola; Robert Zangerle; Pia Handberg; Antonio Antela; Sris Allan; Andrew N Phillips; Jens Lundgren Journal: JAMA Date: 2016-07-12 Impact factor: 56.272
Authors: Hasina Samji; Angela Cescon; Robert S Hogg; Sharada P Modur; Keri N Althoff; Kate Buchacz; Ann N Burchell; Mardge Cohen; Kelly A Gebo; M John Gill; Amy Justice; Gregory Kirk; Marina B Klein; P Todd Korthuis; Jeff Martin; Sonia Napravnik; Sean B Rourke; Timothy R Sterling; Michael J Silverberg; Stephen Deeks; Lisa P Jacobson; Ronald J Bosch; Mari M Kitahata; James J Goedert; Richard Moore; Stephen J Gange Journal: PLoS One Date: 2013-12-18 Impact factor: 3.240
Authors: Lauren Jennings; Tracy Kellermann; Matthew Spinelli; Zukiswa Nkantsu; Dolphina Cogill; Marije van Schalkwyk; Eric Decloedt; Gert van Zyl; Catherine Orrell; Monica Gandhi Journal: AIDS Res Hum Retroviruses Date: 2021-12-29 Impact factor: 1.723
Authors: Kathy K Byrd; Felicia Hardnett; John G Hou; Patrick G Clay; Sumihiro Suzuki; Nasima M Camp; Michael D Shankle; Paul J Weidle; Michael S Taitel Journal: AIDS Behav Date: 2020-12
Authors: Ram K Shrestha; Jon C Schommer; Michael S Taitel; Oscar W Garza; Nasima M Camp; Osayi E Akinbosoye; Patrick G Clay; Kathy K Byrd Journal: J Acquir Immune Defic Syndr Date: 2020-11-01 Impact factor: 3.771
Authors: Karen Diepstra; Haidong Lu; Kathleen A McManus; Elizabeth T Rogawski McQuade; Anne G Rhodes; Daniel Westreich Journal: AIDS Date: 2020-09-01 Impact factor: 4.632
Authors: D Scott Batey; Xueyuan Dong; Richard P Rogers; Anthony Merriweather; Latesha Elopre; Aadia I Rana; H Irene Hall; Michael J Mugavero Journal: JMIR Public Health Surveill Date: 2020-05-22